Screening for Sickle Cell Disease | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital of New York at NYU Langone screen newborns for sickle cell disease ensuring early treatment.
Screening for Spina Bifida in Children | NYU Langone Health
NYU Langone doctors offer a quadruple screen test, prenatal ultrasound, and amniocentesis to screen for spina bifida during pregnancy.
Screening for Tuberculosis | NYU Langone Health
NYU Langone doctors perform screening tests for people who may have been exposed to tuberculosis.
ScreenPlus: A Comprehensive Flexible Multi-disorder Newborn Screening Program
Shortly after birth, all New York babies have a routine newborn screening (NBS) test that checksfor more than 50 treatable disorders. ScreenPlus is a research study where babies are screenedfor an additional 14 rare disorders that are not currently on NY’s routine NBS panel. All of thedisorders on the ScreenPlus panel have an approved treatment or an investigational therapythat is currently being tested in a clinical trial. ScreenPlus will help us understand how well NBSworks for these disorders. For more information, please reach out to ScreenPlus@nyulangone.org.
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP II)
A Phase II study to assess the safety and efficacy of AVB-114 intreatment of complex Crohn’s perianal fistulas in subjects withquiescent rectal disease and whose fistula has failed to respond tobiologic or conventional therapy. Fistula remission in theinvestigational treatment group will be compared to a standard ofcare control arm.The design is prospective, multicenter, randomized, open-label withblinded outcome assessment, add-on therapy, parallel arm (activecontrol and investigational treatment) study. The study has twoparts:Part 1: includes screening, enrollment, randomization, all studyfollow-up visits for treatment arm subjects, and primary follow-upvisits for control arm subjects.Part 2: control arm subjects that receive AVB-114 treatmentfollowing the Week 36 study visit (primary endpoint) and are thenfollowed for an additional 52 weeks.
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
The purpose of this research study is to assess the safety and efficacy of upadacitinib compared with placebo (fake drug) for the treatment of signs and symptoms in adults with moderately to severely active systemic lupus erythematosus (SLE, also called lupus).
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
The purpose of this program is to assess the safety and efficacy of upadacitinib compared with placebo (fake drug) for the treatment of signs and symptoms in adults with moderately to severely active systemic lupus erythematosus (SLE). Upadacitinib is an experimental drug that blocks the actions of proteins known as Janus kinases (Jaks). Jaks are involved in the immune response and cell growth including blood cells. The study drug has been approved by regulatory authorities to treat other medical conditions such as rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis but is not approved to treat lupus. Therefore, the use of the study drug is investigational (experimental) for the purposes of this program.
Selective Mutism Service | NYU Langone Health
The Selective Mutism Service is located at the Child Study Center, part of Hassenfeld Children’s Hospital at NYU Langone.
Seligman Center for Advanced Therapeutics | NYU Langone Health
NYU Langone’s Seligman Center for Advanced Therapeutics connects patients who have rheumatic conditions with clinical trials.
Seligman Center for Advanced Therapeutics Doctors | NYU Langone Health
Find a doctor at the Seligman Center for Advanced Therapeutics at NYU Langone.